Solid Biosciences (SLDB) Operating Leases (2019 - 2026)

Solid Biosciences has reported Operating Leases for 8 years, with the latest figure at $18.5 million in Q1 2026.

• Quarterly Operating Leases fell 10.57% year-over-year to $18.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.5 million (down 10.57% YoY) and the FY2025 annual result came in at $19.1 million, down 9.93% from the prior year.
• Operating Leases eased to $18.5 million in Q1 2026 per SLDB's latest filing, from $19.1 million in the prior quarter.
• Over five years, Operating Leases peaked at $24.5 million in Q2 2022 and troughed at $70000.0 in Q1 2022.
• A 5-year average of $20.7 million and a median of $22.1 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2023: Operating Leases tumbled 96.46% in 2022, then jumped 34060.0% in 2023.
• Over 5 years, Operating Leases stood at $24.3 million in 2022, then slipped by 6.47% to $22.7 million in 2023, then fell by 6.82% to $21.2 million in 2024, then retreated by 9.93% to $19.1 million in 2025, then fell by 3.04% to $18.5 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $18.5 million, $19.1 million, and $19.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.